Treatment of Acute Pulmonary Embolism with Active Cancer
Clinical Scenario
This protocol addresses acute pulmonary embolism occurring in patients with active cancer. The presence of active malignancy is the defining comorbidity that shapes the anticoagulation approach — standard treatment decisions for this population differ meaningfully from those for patients without cancer.
Treatment Approach (Summary)
Anticoagulation for this population is anchored in subcutaneous, weight-adjusted therapy as the preferred initial strategy over vitamin K antagonists. Depending on the cancer type — specifically whether gastrointestinal cancer is present — certain oral anticoagulant agents may be appropriate alternatives.
The complete protocol — covering preferred agents, alternative options, patient-selection criteria, duration, and adjustments — is available below.
References
DOI: 10.1093/eurheartj/ehz405
For patients with PE and cancer, weight-adjusted subcutaneous LMWH should be considered for the first 6 months over VKAs.
Edoxaban should be considered as an alternative to weight-adjusted subcutaneous LMWH in patients without gastrointestinal cancer.
Rivaroxaban should be considered as an alternative to weight-adjusted subcutaneous LMWH in patients without gastrointestinal cancer.
View source ↗